|Articles|March 11, 2021
- Pharmaceutical Executive-03-01-2021
- Volume 41
- Issue 3
Pharmaceutical Executive, March 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive March 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 5 years ago
The Amazon Effect: A Data-Fueled Customer Experienceabout 5 years ago
Why ESG Performance Metrics Matterabout 5 years ago
Pharma and Biotech’s 2020 Full-Year Viewabout 5 years ago
Persevering for Patientsabout 5 years ago
Biopharma’s Reputation Gets a Well-Earned Shot in the Armabout 5 years ago
IP and Capitalabout 5 years ago
IP and COVID-19about 5 years ago
Pharma Steps Up for Public Health Inequitiesabout 5 years ago
FDA Relays Recent Achievements, Maps Plans for Progressabout 5 years ago
IP and CollaborationAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
2
The Risks and Benefits of FDA Reviewing Real-Time Data
3
Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates
4
FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry
5